# Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

> **NCT02423954** · PHASE1,PHASE2 · TERMINATED · sponsor: **Western Regional Medical Center** · enrollment: 33 (actual)

## Conditions studied

- Advanced Cancer
- Pancreatic Cancer
- Renal Cell Cancer
- Non Small Cell Lung Cancer
- Colorectal Carcinoma
- Endometrial
- Uterine

## Interventions

- **DRUG:** Temsirolimus
- **DRUG:** Irinotecan
- **DRUG:** Irinotecan + capecitabine
- **DRUG:** nivolumab

## Key facts

- **NCT ID:** NCT02423954
- **Lead sponsor:** Western Regional Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2017-11-01
- **Final completion:** 2017-11-01
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Investigator no longer at site to enroll patients or write up data
- **Last updated:** 2018-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02423954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02423954, "Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02423954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*